Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
alpha-1 adrenergic receptor antagonist |
| gptkbp:approvalYear |
2006
|
| gptkbp:ATCCode |
G04CA04
|
| gptkbp:brand |
gptkb:Rapaflo
|
| gptkbp:CASNumber |
160970-54-7
|
| gptkbp:contraindication |
severe renal impairment
severe hepatic impairment |
| gptkbp:drugInteraction |
strong CYP3A4 inhibitors
phosphodiesterase-5 inhibitors |
| gptkbp:eliminationHalfLife |
13 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:firstApproval |
gptkb:Japan
|
| gptkbp:hasMolecularFormula |
C25H32F3N3O4
|
| https://www.w3.org/2000/01/rdf-schema#label |
silodosin
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
selective alpha-1A adrenergic receptor blockade
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
Not recommended
|
| gptkbp:proteinBinding |
97%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:orthostatic_hypotension
dizziness retrograde ejaculation |
| gptkbp:synonym |
gptkb:Rapaflo
KMD-3213 |
| gptkbp:usedFor |
gptkb:benign_prostatic_hyperplasia
|
| gptkbp:bfsParent |
gptkb:Silodyx
|
| gptkbp:bfsLayer |
8
|